Efficacy and Safety of Sofosbuvir/Velpatasvir in Patients With Chronic Hepatitis C Virus Infection Receiving Opioid Substitution Therapy: Analysis of Phase 3 ASTRAL Trials | Zendy

Jason Grebely | Zendy; Gregory J. Dore | Zendy; Stefan Zeuzem | Zendy; Richard Aspinall | Zendy; Raymond Fox | Zendy; Lingling Han | Zendy; John McNally | Zendy; Anu Osinusi | Zendy; Diana M. Brainard | Zendy; G. Mani Subramanian | Zendy; Macky Natha | Zendy; Graham R. Foster | Zendy; Alessandra Mangia | Zendy; Mark Sulkowski | Zendy; Jordan J. Feld | Zendy

Open Access

Efficacy and Safety of Sofosbuvir/Velpatasvir in Patients With Chronic Hepatitis C Virus Infection Receiving Opioid Substitution Therapy: Analysis of Phase 3 ASTRAL Trials

Author(s) -

Jason Grebely,

Gregory J. Dore,

Stefan Zeuzem,

Richard Aspinall,

Raymond Fox,

Lingling Han,

John McNally,

Anu Osinusi,

Diana M. Brainard,

G. Mani Subramanian,

Macky Natha,

Graham R. Foster,

Alessandra Mangia,

Mark Sulkowski,

Jordan J. Feld

Publication year - 2016

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1093/cid/ciw579

Subject(s) - medicine , sofosbuvir , regimen , hepatitis c virus , hepatitis c , opioid , virology , ribavirin , virus , receptor

In this analysis of the ASTRAL trials (non-opioid substitution therapy [OST], n = 984; OST, n = 51) evaluating the once-daily, pan-genotypic regimen of sofosbuvir/velpatasvir for hepatitis C virus infection, OST did not impact completion, adherence, sustained virologic response (SVR12), or safety. SVR12 was 96% (95% confidence interval, 87%, >99%) in those receiving OST.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research